ciprofloxacin has been researched along with zidovudine in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (20.69) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 13 (44.83) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calistri, A; Cecchetti, V; Filipponi, E; Fravolini, A; Gatto, B; Moro, S; Palu', G; Palumbo, M; Parolin, C; Pecere, T; Tabarrini, O | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Charman, WN; Hamann, MT; Hammond, NL; Mayer, AM; McIntosh, KA; Peng, J; Wahyuono, S; Yousaf, M | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Alonso, D; Donia, MS; Franzblau, SG; Garcia-Palomero, E; Hamann, MT; Khan, SI; Martinez, A; Medina, M; Peng, J; Rao, KV; Tekwani, BL; Wahyuono, S; Willett, KL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Ahsan, MJ; Govindasamy, J; Khalilullah, H; Mohan, G; Stables, JP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gazzard, BG; Hawkins, DA; Nelson, MR; Shanson, DC | 1 |
| Allen, RA; Amyes, SG; Lewin, CS | 1 |
| De Gregoris, P; Farinelli, S; Iegri, F; Iona, E; Mascellino, MT | 1 |
| Farinelli, S; Iegri, F; Iona, E; Mascellino, MT | 1 |
| Calderon, C; Casado, JL; Frutos, B; Guerrero, A; Martinez-Beltran, J; Navas, E; Valdezate, S | 1 |
| Bonato, M; Dal Negro, G; Sciuscio, D; Vandin, L | 1 |
| Boyle, DC; Cooper, DL; Lovett, ST | 1 |
| Jung, JA; Kaisar, N; Parvez, MM; Shin, HJ; Shin, JG | 1 |
2 review(s) available for ciprofloxacin and zidovudine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
27 other study(ies) available for ciprofloxacin and zidovudine
| Article | Year |
|---|---|
6-Aminoquinolones as new potential anti-HIV agents.
Topics: Animals; Anti-HIV Agents; Cell Line; Chlorocebus aethiops; DNA, Viral; Herpesvirus 1, Human; HIV-1; Piperazines; Quinolones; Reverse Transcriptase Inhibitors; RNA, Viral; Spectrometry, Fluorescence; Structure-Activity Relationship; Vero Cells | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antifungal Agents; Biological Availability; Carbazoles; Carbolines; Fourier Analysis; HIV-1; Indoles; Injections, Intravenous; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microbial Sensitivity Tests; Models, Molecular; Molecular Conformation; Porifera; Pyrroles; Quinolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2004 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases.
Topics: Alzheimer Disease; Animals; Female; Glycogen Synthase Kinase 3; HIV-1; Humans; Indole Alkaloids; Indonesia; Inhibitory Concentration 50; Leishmania donovani; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Oryzias; Plasmodium falciparum; Porifera; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
POMA analyses as new efficient bioinformatics' platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues.
Topics: Amides; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anticonvulsants; Antifungal Agents; Aspergillus niger; Bacillus subtilis; Candida albicans; Cell Line; Cell Survival; Computational Biology; Escherichia coli; HIV-1; HIV-2; Humans; Mice; Microbial Sensitivity Tests; Motor Activity; Pseudomonas aeruginosa; Pyrazoles; Staphylococcus aureus; Thioamides | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Salmonella, Campylobacter and Shigella in HIV-seropositive patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Campylobacter Infections; CD4-Positive T-Lymphocytes; Ciprofloxacin; Dysentery, Bacillary; Feces; HIV Seropositivity; Humans; Leukocyte Count; Male; Middle Aged; Pneumonia, Pneumocystis; Recurrence; Retrospective Studies; Salmonella Infections; Sepsis; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1992 |
Antibacterial activity of fluoroquinolones in combination with zidovudine.
Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Enoxacin; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Salmonella; Staphylococcus; Zidovudine | 1990 |
In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli.
Topics: Ciprofloxacin; Drug Combinations; Escherichia coli; Microbial Sensitivity Tests; Salmonella; Zidovudine | 1993 |
The influence of the SOS response on the activity of 4-quinolones and zidovudine against some strains of Enterobacteria.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Interactions; Drug Synergism; Escherichia coli; HIV-1; Humans; Microbial Sensitivity Tests; Nalidixic Acid; Pyelitis; Salmonella Infections; Salmonella typhimurium; SOS Response, Genetics; Zidovudine | 1998 |
Zidovudine therapy protects against Salmonella bacteremia recurrence in human immunodeficiency virus-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amoxicillin; Anti-HIV Agents; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Probability; Recurrence; Salmonella Infections; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1999 |
MAC management.
Topics: Acquired Immunodeficiency Syndrome; Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; Clofazimine; Drug Interactions; Drug Therapy, Combination; Ethambutol; Humans; Mycobacterium avium-intracellulare Infection; Rifabutin; Rifampin; Tuberculin Test; Zidovudine | 1996 |
Toward refinement of the colony-forming unit-granulocyte/macrophage clonogenic assay: inclusion of a metabolic system.
Topics: Animals; Cefazolin; Cefotaxime; Ciprofloxacin; Colony-Forming Units Assay; Doxorubicin; Granulocytes; Hematopoietic Stem Cells; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Microsomes, Liver; Rats; Rats, Sprague-Dawley; Valproic Acid; Zidovudine | 2006 |
Genetic analysis of Escherichia coli RadA: functional motifs and genetic interactions.
Topics: Amino Acid Motifs; Anti-Bacterial Agents; Ciprofloxacin; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Escherichia coli; Escherichia coli Proteins; Mutation; Phenotype; Protease La; Protein Interaction Domains and Motifs; Protein Structure, Tertiary; Rec A Recombinases; Recombination, Genetic; Zidovudine; Zinc Fingers | 2015 |
Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family.
Topics: 1-Methyl-4-phenylpyridinium; Aminosalicylic Acid; Animals; Antitubercular Agents; Ciprofloxacin; HEK293 Cells; Humans; Inhibitory Concentration 50; Ion Transport; Kinetics; Levofloxacin; Linezolid; Metformin; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pyrazinamide; Rifabutin; Rifampin; Zidovudine | 2016 |